Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Adicet Bio, Inc. - Common Stock (NQ:ACET)

0.7660 +0.0058 (+0.76%)
Streaming Delayed Price Updated: 9:30 AM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adicet Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Adicet Bio (ACET) Q2 Loss Widens 3%
Via The Motley Fool
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases
From Adicet Bio, Inc.
Via Business Wire
Why Block Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Adicet Bio to Participate in a Fireside Chat at the 2025 Jefferies Global Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Thursday?
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Adicet Bio Appoints Michael Grissinger to the Board of Directors
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress
From Adicet Bio, Inc.
Via Business Wire
Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc)
From Adicet Bio, Inc.
Via Business Wire
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe
Via Stocktwits
Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
From Adicet Bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.